Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies

Anti-CD47 mAb can quench DEMs while exposing pro-phagocytic signals, promoting tumor cell phagocytosis. ALK inhibitors induced immunogenic cell damage by upregulating CALR in both sensitive and off-target resistant tumors. Continuous TKIs exposure in off-target resistant settings also resulted in the upregulation of CD47 over time. Combining TKIs with a CD47 blockade may offer therapeutic benefits in ALK+ cancers, especially in overcoming off-target resistance where TKIs alone are less effective.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2024-12-12
DOI
https://doi.org/10.3390/biomedicines12122819
Citations
1
Primary Topic
Phagocytosis and Immune Regulation
Type
article
Field-Weighted Citation Impact
0.24

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies

Chiara Scollo, Ilaria Crespiatico, Elisa Bossi, Daniele Ramazzotti et al.
1 citations
Biomedicines
Phagocytosis and Immune Regulation
0.24
article

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies

Chiara Scollo, Ilaria Crespiatico, Elisa Bossi, Daniele Ramazzotti, Andrea Aroldi, Carolina Steidl, Carlo Gambacorti‐Passerini, Federica Cocito, Rocco Piazza, Luca Mologni, Mario Mauri, Federica Malighetti, Valentina Crippa, Matteo Villa, Ivan Civettini, Simone Piane
article en
1 citations

Abstract

Anti-CD47 mAb can quench DEMs while exposing pro-phagocytic signals, promoting tumor cell phagocytosis. ALK inhibitors induced immunogenic cell damage by upregulating CALR in both sensitive and off-target resistant tumors. Continuous TKIs exposure in off-target resistant settings also resulted in the upregulation of CD47 over time. Combining TKIs with a CD47 blockade may offer therapeutic benefits in ALK+ cancers, especially in overcoming off-target resistance where TKIs alone are less effective.

BiomedicinesVol. 12(12)
Boston Children's Hospital (US), Harvard University (US), Vita-Salute San Raffaele University (IT), Azienda Ospedaliera San Gerardo (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), University of Milano-Bicocca (IT)
Dipartimenti di Eccellenza, European Commission, Associazione Italiana per la Ricerca sul Cancro
Good health and well-being
Openalex Percentile: Top 40%
Phagocytosis and Immune Regulation
0.24
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.